Northern Ireland on the edge: Mounjaro prices explode, supply tightens, black-market booms

Martin Murphy·
Medication and Product InfoNews

Eli Lilly is delivering more than a price bump, it is a price explosion. From 1 September 2025, the UK list price for Mounjaro®️ (tirzepatide), used in type 2 diabetes and weight loss treatment, will rise sharply by up to around 170 per cent. The highest dose sees one of the steepest jumps, while lower doses also climb significantly, with increases ranging between around 45 and 138 per cent.

Lilly is bringing UK prices into line with the rest of Europe. The lower launch price helped Community Pharmacies adopt Mounjaro quickly, but from September the company will reset the price to match its wider market strategy.

What it means for pharmacy

⁠Private-Sector Impact

Community pharmacies that dispense Mounjaro privately will face higher wholesale costs, which can affect both:

– Pricing transparency: Patients will see a sharp increase for self-funded treatment. This could lead to awkward conversations at the counter and pressure on pharmacies to justify prices they do not control.
– Demand shifts: Some patients may choose to delay, reduce dosage, or stop treatment altogether if they cannot afford the new rates, changing dispensing patterns.
Supply Strain
Even without a shortage, pharmacies may face tighter supply management due to increased demand and changes in purchasing patterns. This can mean:
 
– More stock-monitoring admin: Placing orders earlier, managing allocations, and advising patients about availability timelines.
– Switch conversations: Guiding patients through dose adjustments or KwikPen usage if certain presentations are not immediately available.
Workload on Patient Communication
Pharmacists will need to be proactive in explaining the reasons behind price changes, calming concerns, and ensuring patients understand their options.
This extra communication load can:
 
– Take time away from clinical services
– Require clear, consistent messaging to avoid confusion
⁠Risk of Unregulated Sources
As private prices climb, some patients may look for cheaper or faster access online or through social media sellers. Community pharmacies are often the first to spot this risk and will need to:
 
– Warn patients about counterfeit or unsafe products
– Direct them back into regulated care pathways

What It Means for Patients

For many patients using Mounjaro, the treatment is more than a convenience, it is a lifeline for improving health, managing type 2 diabetes, and supporting weight loss. Some have already made significant financial sacrifices, giving up other non-essential spending or even essential items in order to afford the weight loss journey they are on.

With higher prices in the private market, this balancing act becomes much harder. The risk is that patients who have worked hard to lose weight and improve their health could be forced to reduce their dose, skip treatment, or stop altogether. This can increase the likelihood of regaining lost weight and falling back into obesity, undoing months or even years of progress.

The emotional impact should not be underestimated. Patients who have seen real health improvements may feel frustrated, anxious, or defeated if the treatment they have invested in is suddenly out of reach. Without clear support and affordable access, some could turn to unregulated sources, creating both health and safety risks.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Supply squeeze: shortage warning lights flashing

High-dose pens have faced ongoing shortages in the UK, with demand continuing to exceed supply. Although availability of lower doses has improved, it remains fragile.

The latest price announcement is expected to add further strain, prompting patients to stock up ahead of the increase and some pharmacies to maximise sales while the lower prices still apply.

black market risk

We cannot ignore the serious risks that were already building before this price rise, with people turning to unregulated sellers, black-market supply chains, and counterfeit versions of Mounjaro.

Investigations have uncovered social-media accounts, beauty salons, and online “clinics” offering the drug without prescriptions or medical checks, sometimes selling pens of unknown origin. Counterfeit products have been linked to severe side effects, hospitalisations, and even deaths in Northern Ireland, with some fake injections found to contain entirely different, and potentially dangerous, substances.

This shadow market thrives when legitimate access is limited, making it even more important for patients to use regulated pharmacy channels and for healthcare teams to warn against the life-threatening consequences of buying outside them.

WATCH THIS SPACE 

For now, all we can do is monitor what lies ahead for Mounjaro supply in pharmacies as the higher costs take hold. The priority is to act quickly, be ready to support patients, and keep their weight-loss journeys on track. Keep communication clear, keep them informed, and put a solid plan in place for pricing and supply in the months ahead.